Stay in touch
Prime news from our network.
#read
Strategic partnership for radiomolecular precision oncology in Munich
The International Centers for Precision Oncology Foundation (ICPO) and Munich Precision Oncology GmbH (MPO) have announced a partnership to establish a pilot centre for radiomolecular cancer therapy in Garching near Munich. This state-of-the-art centre will set new standards in precision oncology and serve as a model for future theranostic centres worldwide.
18/11/2024
The centre is being established in collaboration with leading clinical, academic and industrial partners. It combines state-of-the-art technologies such as a whole-body PET/CT scanner with AI-powered data analysis to develop innovative diagnostic and treatment options. One focus is on conducting clinical trials and developing new radiopharmaceuticals to bridge the gap between research and patient care. The ICPO Foundation brings its international accreditation model, which includes practical training, certified training programmes and guidelines for patient procedures and clinical protocols. The aim is to improve the quality of care and set global standards for precision oncology. Odile Jaume, CEO of the ICPO Foundation, sees the partnership as a key to democratising access to precision oncology. Dr Bent Witte-Reichardt, Managing Director of MPO, describes the pilot centre as a model for patient-oriented, innovative cancer therapies that can be replicated worldwide. The aim is to significantly improve global cancer care through state-of-the-art theranostics. By combining cutting-edge technology, interdisciplinary collaboration and a focus on clinical excellence, the Munich pilot centre is setting new standards in cancer therapy.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.